Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window

This article was originally published in The Tan Sheet

Executive Summary

The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit

You may also be interested in...

Declaratory Orders For Drug Firms Could Come Easier With High Court Ruling

The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could come in a case brought by Teva against Novartis regarding Famvir

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts